Adult T-cell leukemia/lymphoma

Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare cancer of the immune system's T-cells<ref name="pmid4544052">Template:Cite journal</ref><ref name="pmid301762">Template:Cite journal</ref><ref name="pmid22068231">Template:Cite journal</ref> caused by human T cell leukemia/lymphotropic virus type 1 (HTLV-1).<ref name="pmid15726602">Template:Cite journal</ref> All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm.<ref name="pmid15726602" /> A small number of HTLV-1 individuals progress to develop ATL with a long latency period between infection and ATL development. ATL is categorized into four subtypes: acute, smoldering, lymphoma-type, and chronic. Acute and lymphoma-type are known to particularly be aggressive with poorer prognosis.<ref name=":1">Template:Cite journal</ref>

Globally, the retrovirus HTLV-1 is estimated to infect 20 million people per year with the incidence of ATL approximately 0.05 per 100,000 per year with endemic regions such as regions of Japan, as high as 27 per 100,000 per year.<ref name=":0">Template:Cite journal</ref> However, cases have increased in non-endemic regions with highest incidence of HTLV-1 in southern/northern islands of Japan, Caribbean, Central and South America, intertropical Africa, Romania, northern Iran. ATL normally occurs around the age of 62 years but median age at diagnosis does depend on prevalence of the HTLV-1 infection in the geographic location.<ref name=":2">Template:Cite journal</ref>

Current treatment regimens for ATL are based on clinical subtype and response to initial therapy. Some therapy modalities for treatment may not be available in all countries therefore strategies differ across the world. All patients are referred to clinical trials if available. Beyond clinical trials, treatments are centered on multiagent chemotherapy, zidovudine plus interferon-a (AZT/IFN), and allogeneic hematopoietic stem cell transplantation (alloHSCT).<ref name=":0" />

Signs and symptoms

ATL is usually a highly aggressive non-Hodgkin's lymphoma with no characteristic histologic appearance except for a diffuse pattern and a mature T-cell phenotype.<ref>Template:Cite journal</ref> Circulating lymphocytes with an irregular nuclear contour (leukemic cells) are frequently seen. Several lines of evidence suggest that HTLV-1 causes ATL. This evidence includes the frequent isolation of HTLV-1 from patients with this disease and the detection of HTLV-1 proviral genome in ATL leukemic cells. ATL is frequently accompanied by visceral involvement, hypercalcemia, skin lesions, and lytic bone lesions. Bone invasion and osteolysis, features of bone metastases, commonly occur in the setting of advanced solid tumors, such as breast, prostate, and lung cancers, but are less common in hematologic malignancies. However, patients with HTLV–1–induced ATL and multiple myeloma are predisposed to the development of tumor-induced osteolysis and hypercalcemia. One of the striking features of ATL and multiple myeloma induced bone disease is that the bone lesions are predominantly osteolytic with little associated osteoblastic activity. In patients with ATL, elevated serum levels of IL-1, TGFβ, PTHrP, macrophage inflammatory protein (MIP-1α), and receptor activator of nuclear factor-κB ligand (RANKL) have been associated with hypercalcemia. Immunodeficient mice that received implants with leukemic cells from patients with ATL or HTLV–1–infected lymphocytes developed hypercalcemia and elevated serum levels of PTHrP.<ref name="pmid16118323">Template:Cite journal</ref> Most patients die within one year of diagnosis.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Infection with HTLV-1, like infection with other retroviruses, probably occurs for life and can be inferred when antibody against HTLV-1 is detected in the serum.<ref name="pmid16155611" />

Transmission

Transmission of HTLV-1 is believed to occur from mother to child; by sexual contact; and through exposure to contaminated blood, either through blood transfusion or sharing of contaminated needles.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Diagnosis

Diagnosis is based on clinical features and characteristic morphologic and immunophenotypic changes of malignant cells. As clinical features and prognosis can be diverse, the disease is subtype-classified into four categories according to the Shimoyama classification: acute, lymphoma, chronic, and smoldering.<ref>Template:Cite journal</ref> Normally, identification of at least 5 percent of tumor cells in peripheral blood and confirmation of human T-lymphotropic virus type-1 are sufficient for diagnosis of acute, chronic, and smoldering types. For the lymphoma type, histopathologic examination by biopsy of lymph nodes may be needed.<ref>Template:Cite journal</ref>

The immunophenotype of ATLL includes positive markers such as CD2, CD3, CD4, CD5, and CD25, with negative markers for CD7, CD8, and cytotoxic markers. Additionally, there is partial positivity for CD30, CCR4, and FOXP3.<ref>Template:Cite journal</ref>

Treatment

Treatment options that have been tried include zidovudine and the CHOP regimen.<ref name="pmid16155611">Template:Cite journal</ref> Pralatrexate has also been investigated.<ref name="pmid19389878">Template:Cite journal</ref> Recently, it has been reported that the traditional glucocorticoid-based chemotherapy toward ATL is largely mediated by thioredoxin binding protein-2 (TBP-2/TXNIP/VDUP1), suggesting the potential use of a TBP-2 inducer as a novel therapeutic target.<ref name="pmid21151022">Template:Cite journal</ref><ref name=pmid20398702>Template:Cite journal</ref>

In 2021, mogamulizumab was approved for relapsed/refractor treatment of ATL in Japan.<ref>Template:Cite journal</ref>

At a medical conference in December 2013, researchers reported anywhere from 21 to 50% of ATL patients have disease expressing CD30.<ref>Campuzano-Zuluaga, G; Pimentel, A; Diaz, L; Chapman-Fredricks, J; and Ramos, J (2013). "CD30 Expression Is Associated With Decreased Survival In Patients With Acute and Unfavorable Chronic Types Of Adult T-Cell Leukemia-Lymphoma" https://ash.confex.com/ash/2013/webprogram/Paper64702.html</ref> Although not FDA approved, treatment with CD30-targeting brentuximab vedotin in CD 30+ cases may be beneficial and supported by current NCCN guidelines.<ref>Template:Cite journal</ref>

Epidemiology

HTLV-1 infection in the United States appears to be rare. Although little serologic data exists, the prevalence of infection is thought to be highest among African Americans living in the Southeast. A prevalence rate of 30% has been found among African-American intravenous drug users in New Jersey, and a rate of 49% has been found in a similar group in New Orleans. The prevalence of infection may be increasing in this risk group. Studies of HTLV-1 antibody indicate that the virus is endemic in southern Japan, in the Caribbean, South America, and in Africa.<ref name=":2" />

ATL is relatively uncommon among those infected with HTLV-1. The overall incidence of ATL is estimated at 1 per 1,500 adult HTLV-1 carriers per year. Those cases that have been reported have occurred mostly among persons from the Caribbean or African Americans from the Southeast United States (National Institutes of Health, unpublished data). There appears to be a long latent period between HTLV-1 infection and the start of ATL.<ref name=":1" />

Research

Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation. Pralatrexate is one compound currently under investigation to treat PTCL.<ref name="pmid19389878" />

Further reading

• Template:Cite book
• Template:Cite journal
• Genoveffa Franchini's NCI page: Human Retroviral Diseases: Pathogenesis and Prevention
• International Retrovirology Association